» Articles » PMID: 33939639

Impact of a Measles and Rubella Vaccination Campaign on Seroprevalence in Southern Province, Zambia

Overview
Specialty Tropical Medicine
Date 2021 May 3
PMID 33939639
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Zambia conducted a measles and rubella (MR) vaccination campaign targeting children 9 months to younger than 15 years of age in 2016. This campaign was the first introduction of a rubella-containing vaccine in Zambia. To evaluate the impact of the campaign, we compared the MR seroprevalence estimates from serosurveys conducted before and after the campaign in Southern Province, Zambia. The measles seroprevalence increased from 77.8% (95% confidence interval [CI], 73.2-81.9) to 96.4% (95% CI, 91.7-98.5) among children younger than 15 years. The rubella seroprevalence increased from 51.3% (95% CI, 45.6-57.0) to 98.3% (95% CI, 95.5-99.4). After the campaign, slightly lower seroprevalence remained for young adults 15 to 19 years old, who were not included in the campaign because of their age. These serosurveys highlighted the significant impact of the vaccination campaign and identified immunity gaps for those beyond the targeted vaccination age. Continued monitoring of population immunity can signal the need for future targeted vaccination strategies.

Citing Articles

Inequalities in measles immunization coverage among two-year-olds in Sierra Leone, 2008-2019.

Osborne A, Bai-Sesay A, Sesay U, Tommy A, Bangura C, Ahinkorah B BMC Infect Dis. 2024; 24(1):1280.

PMID: 39528983 PMC: 11555794. DOI: 10.1186/s12879-024-10088-7.


Serosurveillance for Measles and Rubella.

Brady A, El-Badry E, Padron-Regalado E, Escudero Gonzalez N, Joo D, Rota P Vaccines (Basel). 2024; 12(7).

PMID: 39066453 PMC: 11281569. DOI: 10.3390/vaccines12070816.


Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020.

Murhekar M, Gupta N, Hasan A, Kumar M, Saravana Kumar V, Prosperi C Lancet Glob Health. 2022; 10(11):e1655-e1664.

PMID: 36240831 PMC: 9579355. DOI: 10.1016/S2214-109X(22)00379-5.


Measles immunity gap among reproductive-age women participating in a simulated HIV vaccine efficacy trial in Zambia.

Malama K, Tichacek A, Kelly H, Parker R, Inambao M, Sharkey T Hum Vaccin Immunother. 2022; 18(5):2066426.

PMID: 35446726 PMC: 9302517. DOI: 10.1080/21645515.2022.2066426.


Epidemiological analysis of rubella-confirmed cases from measles suspected cases in Ethiopia: Threat for Congenital Rubella Syndrome.

Gemechu D, Worku Y, Edae Z, Feyisa Y, Watere S, Woyessa A Epidemiol Infect. 2022; :1-18.

PMID: 35225215 PMC: 8915192. DOI: 10.1017/S0950268822000279.